Healthcare / Pharmaceutical RetailersCanadian Sec
$0.07
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.2M · quality 41.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
3.3x
↓EV/EBITDA
1.7x
↓ROE
47.3%
↑Gross Margin
39.0%
↓Debt/Equity
5.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.5%
FCF CAGR
+39.1%
FCF margin
5.8%
FCF / Net income
4.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $40.2M · net income $561758.0 · FCF $2.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $40.2M | $40.2M | $34.1M | $25.9M | $17.7M |
| Net Income | $561758.00 | $561758.00 | $-2.0M | $7.7M | $-8.8M |
| EBITDA | $3.6M | $3.6M | $823418.00 | $10.4M | $-6.7M |
| EPS | 0.02 | 0.02 | -0.07 | 0.27 | -0.65 |
| Gross Margin | 39.0% | 39.0% | 40.0% | 47.1% | 44.2% |
| Operating Margin | 2.9% | 2.9% | -0.2% | 1.8% | -5.9% |
| Net Margin | 1.4% | 1.4% | -5.8% | 29.6% | -50.0% |
| Balance Sheet | |||||
| Debt/Equity | 5.52 | 5.52 | 15.86 | 3.24 | -2.13 |
| Current Ratio | 0.91 | 0.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.3M | $2.3M | $1.6M | $2.2M | $867331.00 |
| Returns | |||||
| ROE | 47.3% | 47.3% | -518.4% | 355.6% | 103.9% |
| Valuation | |||||
| P/E | 3.25 | 3.25 | — | 0.50 | — |
| EV/EBITDA | 1.72 | 1.72 | 9.90 | 0.92 | — |
| P/B | 1.59 | 1.59 | 9.89 | 1.79 | — |
| Growth & Yield | |||||
| Revenue Growth | 18.0% | 18.0% | 31.4% | 46.7% | — |
| EPS Growth | 128.6% | 128.6% | -125.9% | 141.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-33.9%
EPS terminal req.
$0.01
Spread vs growth
162.5%
5Y implied EPS CAGR
-19.0%
EPS terminal req.
$0.01
Spread vs growth
147.6%
10Y implied EPS CAGR
-5.6%
EPS terminal req.
$0.01
Spread vs growth
134.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → 0.02
Residual
-23.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.